Bangladesh TB Leaders Build Momentum for Shorter, Safer Drug-Resistant Tuberculosis Treatment
Capacity building program in the Philippines empowers Bangladesh NTP managers to scale up BPaL and BPaL/M regimens MAKATI CITY, PHILIPPINES—PeerLINC
Access News
New Study Affirms Financial and Public Health Advantages of Treating Drug-Resistant TB with BPaL-Based Regimens in India
A new economic evaluation has added powerful evidence to the already strong case for wide, global adoption of BPaL and
TB Alliance’s DR-TB Treatment Rollout Recognized by WHO as Model for Responsible & Effective Antibiotic Introduction
The World Health Organization’s (WHO) new guidance on Country Preparedness for the Introduction and Appropriate Use of Antibiotics highlighted TB
Indonesian Ministry of Health and TB Alliance Enter Strategic Partnership to Advance Innovations in TB and Mycobacterial Diseases
Collaboration Aims to Strengthen Health Systems and Accelerate Development of Next-Generation Treatments JAKARTA (July 30, 2025)—The Ministry of Health of
TB Experts Rally Around New, Shortened TB Treatments
Regional meeting in Peru convened by PeerLINC, a global peer-to-peer initiative, brings together 20 countries to accelerate collaboration and scale-up
Price of Key DR-TB Medicine Drops 25% as TB Alliance’s Multi-Manufacturer Strategy Expands Access
TB Alliance’s third licensed manufacturer makes pretomanid available through the Global Drug Facility, further improving affordability and access TB Alliance
PeerLINC Recognizes One Year of Transforming Drug-Resistant TB Treatment Through Faster, More Easily Accessible Technical Assistance
The PeerLINC Knowledge Hub, an innovative peer-to-peer initiative that connects experts from countries that rapidly adopted new six-month all-oral drug-resistant
TB Alliance Works With Stop TB Canada, Viatris, and Local Physicians to Speed Pretomanid Access in Canada
Stop TB Canada has announced a streamlined process to speed up the availability of pretomanid, a key drug in the
Historically Successful Global Access Campaign for Pretomanid and BPaL-based Regimens Continues with Major Milestones in BRICS Countries
Throughout 2024, one of TB Alliance’s foremost priorities has been ensuring that pretomanid and BPaL-based regimens reach all people with
TB Alliance Applauds WHO Prequalification of Macleods Pretomanid Product
NEW YORK (November 6, 2024) — Macleods, a pharmaceutical company headquartered in India, has received prequalification from the World Health